Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 41

recruiting
3 987
countries
28
conditions
2 109

820 trials match your criteria

Triple negative breast cancer

Not recruiting

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Non-small cell lung cancer recurrent+1

Not recruiting

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen

Cystic fibrosis respiratory infection suppression

Not recruiting

Study of inhaled BX004 bacteriophage treatment for adults with cystic fibrosis who have chronic Pseudomonas aeruginosa lung infection

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IHMA-2121771-1

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Severe myoclonic epilepsy of infancy

Not recruiting

Study of zorevunersen to reduce seizures in patients with Dravet syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zorevunersen sodium

Meningococcal infection

Not recruiting

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide

Primary hyperaldosteronism

Not recruiting

Study of baxdrostat compared to placebo to treat adults with primary aldosteronism

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat

Idiopathic pulmonary fibrosis

Not recruiting

Study of BI 765423 given by intravenous infusion for patients with idiopathic pulmonary fibrosis with or without standard treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 765423

Hidradenitis

Not recruiting

Study of ruxolitinib cream for treating hidradenitis suppurativa in adult patients

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib

Migraine

Not recruiting

Study of Rimegepant for Prevention of Menstrual Migraine in Women Aged 18-45 Years

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Rimegepant

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.